News
-
-
PRESS RELEASE
Gerresheimer Delivers Solid Results in the Financial Year 2024 Despite Market Headwinds
Gerresheimer reports solid financial results in 2024 with revenue up 2.9% and adjusted EBITDA up 4.1%. Strategies for growth include expansions and focus on biologics solutions. Bormioli Pharma integration to boost revenues from 2025 -
-
-
-
-
-
-
-
PRESS RELEASE
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group
Gerresheimer successfully completes acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, strengthening market position in pharma and biotech industries with complementary product portfolio and broader European footprint